Tough times require sharp strategies – and the right expertise
The industry’s financing climate has slowed down considerably. Investments in the development of pharmaceuticals and medtech are more cautious, and Ulrika Hammarström, Head of CRO at Aurevia, emphasizes that the requirements for a clear market and regulatory strategy have never been higher. For pharmaceutical, biotech and medical device companies that want to reach the market and remain there, she underscores that expert support is no longer an option, but a must.
As Anna-Karin Alm, Head of Quality Assurance and Regulatory Affairs (QARA) at Aurevia puts it: “Medical device companies operate in an extremely challenging environment right now, both in terms of requirements for product development but also in terms of business strategy. Conditions are constantly changing – today faster than ever. Given the global uncertainty, especially related to trade policy, it is crucial to understand how to create – and maintain – success in your business. We guide companies all the way, from early development to market entry and beyond. It is not enough to just get a product approved; It’s about achieving success in the market by anticipating changes that may affect the product’s lifecycle and staying up to date on regulatory requirements.”
